説明
Metabolomic profiling data from the randomized controlled trial of GTB1 in diarrhea-predominant IBS, illustrating metabolite changes between treatment groups. Differential metabolites may reflect the probiotic's influence on gut metabolic pathways.
Figure 11
ChartSource Paper
Effect of Oral Intake of Lactiplantibacillus plantarum APsulloc 331261 (GTB1TM) on Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Study.Cite This Figure
![Figure 11: Metabolomic profiling data from the randomized controlled trial of GTB1 in diarrhea-predominant IBS, illustrating metabolite changes between treatment groups. Differential metabolites may reflect the probiotic's influence on gut metabolic pathways.]() > Source: Kyoungmi Jung et al. "Effect of Oral Intake of Lactiplantibacillus plantarum APsulloc 331261 (GTB1TM) ." *Nutrients*, 2022. PMID: [35631156](https://pubmed.ncbi.nlm.nih.gov/35631156/)
<figure> <img src="" alt="Metabolomic profiling data from the randomized controlled trial of GTB1 in diarrhea-predominant IBS, illustrating metabolite changes between treatment groups. Differential metabolites may reflect the probiotic's influence on gut metabolic pathways." /> <figcaption>Figure 11. Metabolomic profiling data from the randomized controlled trial of GTB1 in diarrhea-predominant IBS, illustrating metabolite changes between treatment groups. Differential metabolites may reflect the probiotic's influence on gut metabolic pathways.<br> Source: Kyoungmi Jung et al. "Effect of Oral Intake of Lactiplantibacillus plantarum APsulloc 331261 (GTB1TM) ." <em>Nutrients</em>, 2022. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/35631156/">35631156</a></figcaption> </figure>